Quanxin Bio-B Long-Acting Bispecific Antibody QX027N Injection Receives Approval for Two Clinical Trials
November 15, 2025
Source: drugdu
105
On November 13, Quanxin Bio-B (02509) issued an announcement stating that its independently developed long-acting bispecific antibody QX027N injection has obtained implied approval for clinical trials from the Center for Drug Evaluation of the National Medical Products Administration, with acceptance numbers CXSL2500757 and CXSL2500758.
This drug is intended for the treatment of asthma and atopic dermatitis, marking the official entry of the company's innovative dual-antibody matrix in the field of autoimmune and allergic diseases into the clinical stage.
https://finance.eastmoney.com/a/202511143564486287.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
